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The replication of murine leukemia virus (MuLV) requires the capture of a cellular tRNAPro as a primer for reverse transcription. To further
study the specificity of primer selection, we have utilized a defective MuLV in which the primer-binding site (PBS) has been altered to be
complementary to a nonmammalian tRNA, yeast tRNAPhe. Infectivity of the defective MuLV is dependent upon co-expression of yeast
tRNAPhe in the cell. Defective MuLV genomes have been constructed in which the PBS was altered to be complementary to tRNAPhe that also
encoded the cDNA for tRNAPhe. Transfection of these defective proviral genomes into cells resulted in the production of infectious MuLVas
determined by a single-round assay. The amount of infectious virus produced using this complementation system, though, was approximately
6-fold lower than that produced following transfection of defective proviral genomes with a wild-type PBS complementary to tRNAPro. The
lower infectivity was not due to reduced expression of tRNAPhe in the transfected cells as compared to endogenous tRNAPro or tRNALys,3.
Serial passage of the MuLV genome with a PBS complementary to tRNAPhe that encoded tRNAPhe resulted in amplification of the virus. Using
this rescue system, we have passaged the virus for four serial passages, after which time a revertant genome in which the PBS was altered to be
complementary to tRNAGln was detected that grew to high titers following subsequent serial passage. The results of these studies suggest that
MuLV has preferences for the tRNA primer used in reverse transcription and are discussed with respect to the mechanism of primer selection.
D 2004 Elsevier Inc. All rights reserved.Keywords: MuLV; Primer-binding site; tRNA; Reverse transcriptionIntroduction
A hallmark of retrovirus replication is the process in
which the viral RNA genome is converted into a DNA
intermediate before integration into the host cell chromo-
some. This process, termed reverse transcription, is cata-
lyzed by a virus-encoded enzyme reverse transcriptase
(Baltimore, 1970; Temin and Mizutani, 1970). The initiation
of reverse transcription occurs at a site in the viral genome
designated as the primer-binding site (PBS), which is
complementary to the 3V terminal 18 nucleotides of a
cellular tRNA molecule that is used as a primer for reverse
transcription (Panet and Berliner, 1978; Peters and Dahl-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: caseym@uab.edu (C.D. Morrow).berg, 1979; Temin, 1981). The reverse transcriptase copies
the viral RNA genome giving rise to a complete copy
consisting of a long terminal repeat (LTR) followed by the
genes encoding the viral proteins and a second LTR (Gilboa
et al., 1979; Taylor and Hsu, 1980; Varmus, 1982). The
complete viral genome, or provirus, is the substrate for the
virus-encoded integrase protein molecule that catalyzes the
integration into the host cell chromosome.
The process of tRNA selection by retroviruses is a crucial
step in the virus life cycle. Retroviruses have evolved to
select a specific tRNA for use as a primer for reverse
transcription (Colicelli and Goff, 1986; Mak and Kleiman,
1997; Marquet et al., 1995). For example, all lentiviruses
use tRNALys,3 while avian leukosis virus (ALV) uses
tRNATrp. Murine leukemia virus (MuLV) has evolved to
specifically select tRNAPro, while mouse mammary tumor
virus (MMTV) selects tRNALys,3 from the intracellular
milieu for use as a replication primer. In recent years, it
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use a wide variety of tRNA primers when the PBS is altered
to be complementary to the 3V terminal nucleotides of the
tRNA (Das et al., 1995; Li et al., 1994; Wakefield et al.,
1995; Whitcomb et al., 1995). Previous studies have also
shown that alteration of the MuLV PBS to tRNAs other than
tRNAPro will also result in the production of an infectious
virus. These studies relied on the use of defective viral
genomes that were complemented by packaging cell lines
that expressed the viral gag, pol, and env (Lund et al., 1993,
1997). In fact, sufficient flexibility exists in the MuLV
primer selection process that artificial tRNAs, that is, tRNAs
with engineered 3V 18 terminal nucleotides that are not
found in nature, can be selected by MuLV following
transfection into cells (Lund et al., 1997).
Although HIV-1 and ALV viruses were generated that
could utilize alternative tRNAs for replication, a common
feature of these studies is that the mutant viruses revert back
to utilize the wild-type tRNA primer (tRNALys,3 for HIV-1
and tRNATrp for ALV) (Das et al., 1995; Li et al., 1994;
Wakefield et al., 1995; Whitcomb et al., 1995). In contrast to
HIV-1 and ALV, a MuLV has been isolated and character-
ized that utilizes an alternative tRNA, tRNAGln, as the
replication primer. The growth characteristics of this virus
appeared to be similar to the wild-type virus when analyzed
in murine or rat cell lines (Colicelli and Goff, 1986). Thus, it
is possible that the tRNA selection process for MuLV could
have fundamental differences from that for HIV-1 and ALV.
In the current study, we have further examined the primer
selection process for MuLV. We have generated recombinant
defective MuLV genomes in which the PBS has been altered
to a tRNA not found in mammalian cells (yeast tRNAPhe).
Previous studies from our laboratory have shown that yeast
tRNAPhe expressed in mammalian cells undergoes amino-
acylation and incorporation into the translational cycle (Kelly
and Morrow, 2003; Kelly et al., 2003). Co-transfection of a
plasmid encoding the cDNA for yeast tRNAPhe with the
MuLV genomes into packaging cell lines resulted in the
production of infectious virus. Defective MuLV genomes
with a PBS complementary to yeast tRNAPhe that also
encoded the cDNA for yeast tRNAPhe were used to amplify
these defective retroviruses and revealed that MuLV shows a
preference for a PBS complementary to tRNAPro or tRNAGln
for high-level replication. The results of our studies are
discussed with respect to the similarities between HIV-1,
ALV, and MuLV primer selection process.Fig. 1. Complementation of pLEGFP(Phe) with yeast tRNAPhe supplied in
trans. (A) Schematic of the retroviral vector, pLEGFP-C1, with its PBS
changed from one having complementarity to tRNAPro to one having
complementarity to yeast tRNAPhe. (B) The dose response of pLEGFP(Phe)
to yeast tRNAPhe. EcoPack packaging cells were co-transfected with
pLEGFP(Phe) and either pU6PheWT (circles) or pU6Pro (squares).
pLEGFP(Phe) was kept constant at 1.5 Ag while the amounts of pU6PheWT
and pU6Pro were varied as indicated. Supernatants from each transfection
condition were tittered on XC cells by selecting for G418-resistant colonies.
The data are from three independent transfections for each point, with
standard deviations.Results
Complementation of PBS-mutated MuLV vector by yeast
tRNAPhe supplied in trans and in cis
Retroviruses prime reverse transcription using a tRNA
acquired from the host cell that is complementary to 18
nucleotides of the viral genome designated as the primer-binding site (PBS). Although retroviruses select a specific
tRNA as the primer for reverse transcription, they can use
tRNA primers other than those preferred by the wild type
by changing the sequence of the PBS to be complementary
to the 3V terminal nucleotides of the tRNA. In a previous
study, we demonstrated that yeast tRNAPhe can rescue the
defective MuLV proviral vector pLEGFP(Phe) that has a
PBS complementary to the 3V terminal 18 nucleotides of
yeast tRNAPhe (Kelly et al., 2003) (Fig. 1A). As a follow
up to this study, we first established a dose response of
pLEGFP(Phe) to yeast tRNAPhe. A constant amount (1.5
Ag) of pLEGFP(Phe) was co-transfected into the ecotropic
packaging cell line EcoPack cells with increasing amounts
of either pU6Pro or pU6PheWT, plasmids that express
tRNAPro and yeast tRNAPhe, respectively. The resultant
vectors were used to transduce XC cells followed by G418
selection. The addition of pU6Pro yielded no colonies. A
dose-dependent increase in the number of colonies was
seen when pU6PheWT was used (Fig. 1B).
Although the infectivity of viruses derived from trans-
fection of pLEGFP(Phe) was dependent upon pU6PheWT,
we ultimately wanted to establish a system in which the
defective virus would supply its own tRNA primer to
examine the co-evolution of the virus PBS and primer
tRNA following multiple serial passages. Towards this goal,
we next wanted to determine if the retroviral genome could
supply the tRNA primer in cis. The three ‘‘piggyback’’
vectors used in this study are depicted in Fig. 2A. The first
vector, pLEGFP-C1-tPhe, was constructed in which the PBS
Fig. 3. Expression of tRNA molecules in EcoPack cells transfected with
varying amounts of piggyback vector. Northern blotting was used to
analyze total RNA collected from five 100-mm dishes of EcoPack cells 2
days following transfection with pLEGFP(Phe)-tPhe at a cell confluency of
approximately 40%. Lanes 1, 2, 3, 4, and 5 contain 5 Ag total RNA
obtained from dishes transfected with 0, 3, 9, 15, and 21 Ag pLEGFP(Phe)-
tPhe, respectively. Lanes 7, 8, 9, 10, and 11 contain 5, 10, 20, 40, and 80 ng
in vitro transcribed RNA standards, respectively. Standards in the top,
middle, and bottom panels are tRNALys,3, tRNAPro, and yeast tRNAPhe,
respectively. Lanes 13 and 14 contain negative controls. Lane 13 of the top
and bottom panels contains 80 ng in vitro transcribed tRNAPro. Lane 14 of
the top and middle panels contains 80 ng in vitro transcribed yeast
tRNAPhe. Eighty nanograms in vitro transcribed tRNALys,3 appears in lane
13 of the middle panel and in lane 14 of the bottom panel. Lanes 6 and 12
are empty. The blots were probed for the tRNAs indicated at the right. The
amounts of radioactivity were determined by direct scintillation counting of
excised regions. A standard curve was used to estimate the amounts of
tRNA per sample. The average values for tRNAPro (6 ng/5 Ag total RNA)
were comparable to tRNALys,3 (9 ng/5 Ag total RNA). The peak value for
tRNAPhe was approximately 7ng/5 Ag total RNA. This correlates with the
2.5 Ag of plasmid point in Fig. 2.
Fig. 2. Complementation of pLEGFP(Phe) with yeast tRNAPhe supplied in
cis. (A) Schematic of the retroviral piggyback vectors. pLEGFP-C1-tPhe
contains a PBS complementary to tRNAPro along with the cDNA for yeast
tRNAPhe inserted into the multiple cloning site (MCS). pLEGFP(Phe)-tPhe
contains a PBS complementary to yeast tRNAPhe along with the cDNA for
yeast tRNAPhe inserted into the MCS. pLEGFP(Phe)-tPro contains a PBS
complementary to yeast tRNAPhe along with the cDNA for tRNAPro
inserted into the MCS. (B) Titers obtained from the constructs are shown in
panel A. EcoPack packaging cells were transfected with the indicated
amounts of pLEGFP-C1-tPhe (closed circles), pLEGFP(Phe)-tPhe (open
circles), and pLEGFP(Phe)-tPro (squares). Supernatants from each
transfection condition were tittered on XC cells by selecting for G418-
resistant colonies. The data are from three independent transfections for
each point, with standard deviations.
M.T. Palmer, C.D. Morrow / Virology 324 (2004) 430–438432was complementary to tRNAPro and in which the gene for
yeast tRNAPhe was inserted into the multiple cloning site
(MCS). A second vector, pLEGFP(Phe)-tPhe, contained a
PBS complementary to yeast tRNAPhe and the gene encod-
ing yeast tRNAPhe inserted into MCS. Finally, a third vector,
pLEGFP(Phe)-tPro, was constructed in which the PBS was
complementary to yeast tRNAPhe but a gene encoding
tRNAPro was inserted into the MCS.
Increasing amounts of pLEGFP-C1-tPhe, pLEGFP(Phe)-
tPhe, or pLEGFP(Phe)-tPro were transfected into EcoPack
cells and the resultant vectors were titered on XC cells. A
dose-dependent increase in titer was obtained from
pLEGFP(Phe)-tPhe, demonstrating the ability of the vector
genome to supply its own tRNA primer (Fig. 2B). The
specificity of the complementation was established because
pLEGFP(Phe)-tPro was not infectious. Importantly, the trans-
fection with pLEGFP(Phe)-tPhe consistently yielded approx-
imately 6-fold fewer colony-forming units (cfu) than did
pLEGFP-C1-tPhe, indicating that the PBS of MuLV com-
plementary to tRNAPro (i.e., wild type PBS) is preferred to a
PBS complementary to yeast tRNAPhe. It was possible
though that the lower infectivity following transfection withpLEGFP(Phe)-tPhe was due to the lower expression of
tRNAPhe compared to endogenous tRNAs. To address this
possibility, we compared the levels of tRNAPhe expression to
endogenous levels of tRNAPro and tRNALys,3 following
transfection of pLEGFP(Phe)-tPhe into EcoPack cells (Fig.
3). We chose tRNAPro because this tRNA is preferred by the
wild-type MuLV; previous studies have shown that the titer
derived from transfection of plasmids encoding a defective
virus with a PBS complementary to tRNALys,3 was similar to
the wild type, indicating at least for single-round comple-
mentation that tRNALys,3 can substitute for tRNAPro. Five
micrograms of total RNAwas judged to contain an average of
9 ng tRNALys,3 and 6 ng tRNAPro. Under optimized trans-
fection conditions (lane 5, bottom panel, Fig. 3), pLEGFP
(Phe)-tPhe yielded approximately 7 ng yeast tRNAPhe per 5
Ag total RNA. Given a transfection efficiency of approxi-
mately 30%, each transfected cell contained approximately 3-
fold more yeast tRNAPhe than tRNALys,3 or tRNAPro, indi-
cating that MuLV prefers the use of tRNAPro to yeast
tRNAPhe even in the presence of excess tRNAPhe.
Serial propagation of defective MuLVs that encode tRNAs
We next wanted to determine if pLEGFP-C1-tPhe and
pLEGFP(Phe)-tPhe could be passaged through multiple
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M.T. Palmer, C.D. Morrow / Virology 324 (2004) 430–438 433rounds of replication. To circumvent interference to super-
infection, we employed complementary packaging cell lines
in a ‘‘ping-pong’’ amplification scheme (Bestwick et al.,
1988). The ecotropic vector obtained from the transient
transfection of the EcoPack packaging cell line was used
to transduce the RetroPack packaging cell line. Following
selection with G418, the 10A1 pseudotyped vector obtained
from RetroPack producer cells was used to transduce fresh
EcoPack cells. Supernatants from selected EcoPack pro-
ducers were used to transduce RetroPack cells, and so on.
The expression of green fluorescence protein (GFP) from
these vectors provided a rapid means to gauge the success of
each passage. The three piggyback vectors were subjected to
a ping-pong replication protocol. The virus derived from
pLEGFP(Phe)-tPro did not survive the first round of selec-
tion; no colonies were recovered following infection of cells
with the supernatant from cells transfected with this vector.
In contrast, virus derived from pLEGFP-C1-tPhe grew well
throughout each passage. The titers obtained from 10A1 or
ecotropic packaging cell lines ranged from 104 to 105 cfu/
ml. Thus, there appeared to be no deleterious effect from
encoding a tRNA gene in the MCS. The virus derived from
pLEGFP(Phe)-tPhe and pLEGFP-C1-tPhe yielded compa-
rable amounts of cfu/ml from transfection of EcoPack cells.
However, upon passage onto RetroPack cells, followed by
selection for producer cells, the titer of vLEGFP(Phe)-tPhe
recovered in the supernatant dropped, relative to vLEGFP-
C1-tPhe, by approximately 10,000-fold. Expansion of these
colonies and analysis of the PBS from integrated proviruses
revealed that the PBS of vLEGFP(Phe)-tPhe was still
complementary to yeast tRNAPhe (Table 1). Thus, integrated
vLEGFP(Phe)-tPhe provirus genomes produce transducing
particles, albeit at very low levels.
To ascertain the defect underlying the low-level expres-
sion of infectious vLEGFP(Phe)-tPhe from integrated provi-
rus, we first analyzed the expression levels of yeast tRNAPhe
in expanded cell colonies. Although detectable, it was clear
that the levels of yeast tRNAPhe were significantly lower than
those of an endogenous tRNA, tRNALys,3, suggesting that the
defect in the production of infectious virus was due to low
levels of yeast tRNAPhe (Fig. 4A). To address this possibility,
the vLEGFP(Phe)-tPhe RetroPack producer cells were trans-
fected with pU6PheWT. Following transfection, the level of
yeast tRNAPhe increased and the titer of virus released from
these cells increased over 20-fold (300 vs. 13 cfu/ml),
demonstrating that the deficiency in the production of virus
was due to the low levels of yeast tRNAPhe (Fig. 4B).
The low amounts of yeast tRNAPhe expressed from the
integrated genomes that encode the tRNA may be the result
of interference between the retroviral LTR promoter and the
intragenic tRNA promoter. Pol III transcription from a
retroviral vector has been shown (Ilves et al., 1996) to be
improved with the use of a double-copy vector wherein the
foreign insert ends up in both proviral U3 regions; the wild-
type U3 may have its own pol III promoter (Choi and Faller,
1995). Because the pol III transcript derived from the 5V U3
Fig. 4. Expression of yeast tRNAPhe in cells transduced with piggyback
vectors. (A) Northern blot analysis of total RNA collected from 100-mm
dishes of RetroPack cells and XC cells, each transduced with either
vLEGFP-C1-tPhe or vLEGFP(Phe)-tPhe followed by selection with G418.
Top and bottom panels show 60-Ag samples divided equally, run in parallel
halves of the same gel, blotted, and probed for tRNALys,3 (as a control) and
yeast tRNAPhe, respectively. The X-ray film shown in the bottom panel was
exposed 10 times longer than the film shown in the top panel. Lanes 1 and
2, RetroPack cells; lanes 3 and 4, XC cells; lanes 1 and 3, cells transduced
with vLEGFP-C1-tPhe; lanes 2 and 4, cells transduced with vLEGFP(Phe)-
tPhe. (B) Northern blot analysis of total RNA collected from 100-mm
dishes of RetroPack cells following transduction with vLEGFP(Phe)-tPhe
and selection with G418, both before and after transfection with pU6PheWT.
Top and bottom panels show 60-Ag samples divided equally, run in parallel
halves of the same gel, blotted, and probed for tRNALys,3 (as a control) and
yeast tRNAPhe, respectively. The exposure time for the films shown in all
three panels was identical. Lane 1, untransfected RetroPack producer cells;
lane 2, RetroPack producer cells following transfection with pU6PheWT;
lane 3, the highly transfectable 293T cells following transfection with
pU6PheWT (as a positive control). The membrane that was probed for yeast
tRNAPhe (lower panels) was cut between lanes 2 and 3 to prevent the signal
from lane 3 from overwhelming the signal from lane 2.
M.T. Palmer, C.D. Morrow / Virology 324 (2004) 430–438434insert does not overlap with the pol II transcript initiated
immediately downstream of this U3, it is thought that
double-copy vectors reduce the conflict between the respec-
tive transcriptional machineries. To determine if we could
increase tRNA expression from integrated provirus, we
inserted the yeast tRNAPhe gene into the U3 region of
pLEGFP-C1 and of pLEGFP(Phe). One pair of subclones
contained the yeast tRNAPhe cDNA cloned into the NheI
site of U3 while a second pair, also containing the insert at
the NheI site, reproduced 16 base pairs of the U3 as
recommended by Hantzopoulos et al., (1989). Of these
second-generation piggyback vectors, as expected, those
whose PBS was complementary to tRNAPro replicated well
during the ping-pong amplification, demonstrating that
neither subcloning approach had been deleterious to the
vector. However, the new vectors that contained a PBS
complementary to yeast tRNAPhe and that also expressed
yeast tRNAPhe, while producing significant quantities of
infectious vector from transiently transfected cells, did not
result in greater virus yields during ping-pong replication
than did the original vector in which the yeast tRNAPhe gene
was inserted between the MuLV LTRs (data not shown).
Because we were able to rescue the defective virus by
transfection of pU6PheWT, we continued the passage exper-
iment onto EcoPack cells followed by selection. Sufficient
virus was produced in the subsequent rounds to allow for
the serial passage of this virus. In each passage, we derived
selected cells to increase the yield of vLEGFP(Phe)-tPhe. At
passage 4 onto EcoPack cells, we noted an obvious increase
in titer as evidenced by the number of cells expressing GFP.
Sequence analysis of the PBS from integrated proviruses
from these cells revealed that the PBS was now comple-
mentary to tRNAGln (Table 1). Analysis of the nucleotide
sequence of the PBS and flanking regions revealed a match
to that reported by Colicelli and Goff (1986); in this study,
the PBS complementary to tRNAGln was obtained through
recombination with an endogenous proviral sequence em-
bedded in the mouse genome. Based on sequence analysis,
the recombination appears to have occurred about 30 base
pairs downstream of the PBS. Thus, even though we
supplied tRNAPhe at high levels from a plasmid to the
integrated proviral genomes, the replication of the defective
virus was compromised resulting in the selection of a
recombinant with a PBS (and primer use) complementary
to tRNAGln.Discussion
In the current study, we have investigated the selection of
the tRNA primer used by MuLV for reverse transcription. A
set of vectors was designed in which the PBS was made
complementary to yeast tRNAPhe. These viruses were not
infectious unless yeast tRNAPhe was supplied in trans.
Chimeric vectors were constructed that contained the PBS
complementary to yeast tRNAPhe as well as the gene
M.T. Palmer, C.D. Morrow / Virology 324 (2004) 430–438 435encoding yeast tRNAPhe. These piggyback vectors were
infectious for several passages between the ecotropic and
10A1 packaging cell lines. However, the PBS of these
viruses was not stable and recombinants emerged in which
the PBS was complementary to tRNAGln. This PBS was
most probably obtained through recombination with an
endogenous retrovirus sequence known to be present within
NIH 3T3 cells (Colicelli and Goff, 1986), from which the
RetroPack PT67 packaging cell line was derived. Following
recombination, these new viruses with a PBS complemen-
tary to tRNAGln rapidly outgrew the viruses with a PBS
complementary to yeast tRNAPhe.
Previous studies have established that MuLV can accom-
modate a wide variety of tRNA primers for initiation of
reverse transcription (Lund et al., 1993, 1997). Consistent
with the results presented in this study, the alteration of the
PBS to be complementary to these other alternative tRNAs
results in the production of a virus less infectious than the
wild type. The flexibility of MuLV to accommodate differ-
ent tRNAs was highlighted by studies in which a synthetic
tRNA was used to complement replication of defective
MuLV (Lund et al., 1997). In this case, the tRNA was
altered so that the 3V terminal 18 nucleotides did not
correspond to a naturally occurring tRNA. Co-expression
of this tRNA along with the vector with a PBS comple-
mentary to the 3V terminal 18 nucleotides of this tRNA
resulted in the production of an infectious virus. Similarly,
we found that alteration of the PBS of MuLV complemen-
tary to yeast tRNAPhe resulted in a virus that was not
infectious unless yeast tRNAPhe was provided. However,
even under conditions of excess yeast tRNAPhe, it was clear
that the amount of infectious virus produced was lower than
that for the wild type with a PBS complementary to
tRNAPro. The lower infectivity appeared to be due to the
inherent features of tRNAPhe. The lower infectivity cannot
be explained by lower expression levels of yeast tRNAPhe,
because analysis of the expression levels revealed that the
amount of yeast tRNAPhe found in cells was equal to or
greater than that for tRNALys,3 and tRNAPro. In contrast to
previous studies using a synthetic tRNA (Lund et al., 1997),
the tRNAPhe expressed in our system undergoes amino-
acylation and entry into the translational cycle (Kelly and
Morrow, 2003). Thus, the preference for tRNAPro (and
tRNALys,3) then is not due to exclusion of tRNAPhe from
the tRNA biosynthetic pathways.
Previous studies with MuLV have found that, in contrast
to HIV-1 or ALV, the reverse transcriptase does not share a
preference for selection of the tRNA primer used for
initiation of reverse transcription (Lund et al., 1993,
1997). This leads to the suggestion that the primer selection
process was less stringent than that for HIV-1 or ALV.
Consistent with the results presented in this study, HIV-1
with only the PBS altered to be complementary to other
tRNAs is replication competent but reverts back to utilize
the wild-type tRNA primer upon growth in tissue culture
(Das et al., 1995). Previous studies using ALV with a PBScomplementary to tRNAs other than tRNATrp were viable
but reverted back to utilize tRNATrp following continuous in
vitro culture (Whitcomb et al., 1995). The experiments
presented in our study are the first to address the character-
istics of MuLV replication engineered to use an alternative
tRNA primer. In previous studies, the PBS-defective viruses
were rescued by transiently transfecting cells with a plasmid
encoding the cognate tRNA needed to complete a single
round of replication (Lund et al., 1993, 1997). Multiple
rounds of replication would require this transfection for
each passage. To circumvent this, we chose to produce the
yeast tRNAPhe from within the proviral construct. Using
two different locations for the yeast tRNAPhe (internal and
within U3), we found that expression of yeast tRNAPhe was
very low, but detectable during passage between ecotropic
and 10A1 packaging cell lines. We compensated for the low
levels of tRNAPhe by transfection of a plasmid encoding
tRNAPhe during the first passage, which resulted in expres-
sion of tRNAPhe to facilitate replication. However, upon
extended passage, we noted that reversion occurred in
which the low replication virus that used yeast tRNAPhe
was replaced by a virus with a PBS complementary to
tRNAGln. A previous study has shown that MuLV with a
PBS complementary to tRNAGln replicates similarly to wild
type (Colicelli and Goff, 1986). The PBS complementary to
tRNAGln is obtained through recombination with a se-
quence endogenous to the mouse genome. Thus, the selec-
tion for high-level replication has resulted in the use of a
new tRNA primer (tRNAGln). It is interesting though that
the virus did not use tRNAGln or tRNAPro from the
intracellular milieu to facilitate reversion. Previous studies
with HIV-1 and ALV have shown that passage of viruses
with altered PBS results in conversion to wild type via
misplacement of the wild-type primer on the mutant PBS
(Das et al., 1995; Li et al., 1994; Wakefield et al., 1995;
Whitcomb et al., 1995). Given the presence of homologous
sequences within the murine genome, recombination repre-
sents an avenue for the acquisition of altered PBSs by
MuLV that is not available to HIV-1.
Collectively, the results of these studies establish that
MuLV, HIV-1, and ALV have evolved to specifically select
tRNA primers from the intracellular milieu that will be used
for high-level replication. The mechanism for the selection
of specific tRNAs is unknown. For HIV-1, the selection and
use of the tRNA primer for reverse transcription have been
shown to involve regions within U5 as well as the PBS
(Dupuy et al., 2003; Kang and Morrow, 1999; Kang et al.,
1997, 1999; Wakefield et al., 1996; Zhang et al., 1998).
Indeed, previous studies have suggested that an RNA stem
loop structure in U5 encompassing the PBS is involved in
the selection of the tRNA primer used for initiation of
reverse transcription. Although HIV-1 and to some extent
ALV have been shown to have unique structures in the U5
region to facilitate the use of tRNA primers for reverse
transcription, the in vitro interaction between MuLV RNA
and tRNAPro is restricted to the PBS (Fosse et al., 1998).
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for different tRNAs do not result in the virus stably utilizing
that tRNA for replication (Kang et al., 1996). Thus, there
appears to be additional constraints in the selection of
certain tRNAs that can be stably used by HIV-1 as a primer
for reverse transcription. This also appears to be the case for
MuLV. In this instance, MuLV with the PBS complementary
to tRNAGln is stable. Consistent with the results obtained in
this study, where we found the emergence of the defective
MuLV with a PBS complementary to tRNAGln, it appears
that MuLV can accommodate either tRNAPro or tRNAGln
effectively as a replication primer. Additional studies will be
needed to ascertain the role of viral genomic structures as
well as inherent differences between tRNAs that result in the
selective use of certain tRNAs as primers for retrovirus
replication.Materials and methods
Plasmid construction
pLEGFP-C1 (Clontech, Palo Alto, CA) is a MuLV-based
retroviral vector that retains the native PBS complementary
to tRNAPro. The gag–pol and env coding regions have been
replaced by the neo gene, expressed from the 5V LTR; the
defective virus also encodes enhanced GFP, expressed from
a CMV promoter, and a multiple cloning site (MCS). The
GeneEditor in vitro site-directed mutagenesis system
(Promega, Madison, WI) was used to change the PBS in
pLEGFP-C1 to have a sequence complementary to the 3V
terminal 18 nucleotides of yeast tRNAPhe using the primer
5V-GGCAGGGGTCTCCAATCCACAGAATTCG CAC-
CAAATGAAAGACCCC-3V. The resulting plasmid was
named pLEGFP(Phe). Fragments containing the cDNAs
encoding tRNAPro and yeast tRNAPhe were obtained by
double-digesting the previously described plasmids pU6Pro
and pU6PheWT (Kelly et al., 2003) with XhoI and HindIII.
These fragments were ligated into the MCS of pLEGFP-C1
or pLEGFP(Phe). The resulting plasmids were named
pLEGFP-C1-tPhe, pLEGFP(Phe)-tPhe, and pLEGFP(Phe)-
tPro. The integrity of the cDNA inserts was verified by
sequencing.
The 3V end of the infectious MuLV clone p63-2 (Bacheler
and Fan, 1981) was amplified by PCR using Taq polymer-
ase (Invitrogen, Carlsbad, CA) and primers A (5V-
GCGGAATTCTAG TTGCCCCTACAG-3V) and B (5V-
CGGAATTCAATGAAAGACCCCCGCT-3V). The product
was ligated into the pGEM-T Easy vector (Promega) to
yield p3VMuLV(TA) and then sequenced. The U6 promoter
and tRNA-encoding region of pU6PheWT was amplified by
PCR using primers NHEFOR (5V-CTCTGCTAGCTTAAG-
TAACGCCATTTCCTATTTCCCATGATT CCTTC-3V) and
PHE3VXBA (5V-ACGCGTCTAGACCAAAAAATGC-
GAATTCTGTGG-3V). The product was digested with NheI
and XbaI and subsequently ligated into p3VMuLV(TA), thathad been linearized with NheI and dephosphorylated, to
yield p3VMuLV(TA)NheFor. A similar approach was used to
construct p3VMuLV(TA)XbaFor except that the primer
XBAFOR (5V-ACGCGTCTAGACCTATTTCCCAT-
GATTCCTTC-3V) was used in place of the NHEFOR primer
for the PCR reaction and the product was digested with XbaI
alone. Primer SAL1TAIL (5V-CTATAGAGTCGACTAGA-
TAAAATAAAAGATTTTATTTA-3V) and primer B were
used to amplify, with Pfu polymerase (Stratagene,
San Diego, CA), the recombinant LTR region of
p3VMuLV(TA)NheFor and of p3VMuLV(TA)XbaFor by
PCR. The two products were digested with SalI and used
to replace the 3V LTR region of the two retroviral vectors,
pLEGFP-C1 and pLEGFP(Phe), at the SalI and Bst1107I
sites to yield the four second-generation piggyback vectors.
Cell culture, transfection, and vector titration
EcoPack2-293 cells and RetroPack PT67 cells were both
obtained from Clontech. All cells were maintained in
Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 1% antibiotic–antimycotic and 10% fetal
bovine serum. Polyethylenimine (PEI; Sigma, St. Louis,
MO) was used as a transfection reagent (Boussif et al.,
1995). Transfections and vector titrations were performed
as described previously (Kelly et al., 2003). For all trans-
fections, cells were rinsed 2 times the following day with
complete DMEM and samples were collected on the second
day.
Replication of defective viruses
Vector replication by ping-pong amplification has been
described (Bestwick et al., 1988). For our purposes, the
supernatant from transfected EcoPack2-293 cells was used
to transduce RetroPack PT67 cells. RetroPack PT67 cells
were selected with 550 Ag/ml active G418. Following
selection, the supernatant was used to transduce Eco-
Pack2-293 cells. These cells were selected in medium with
550 Ag/ml active G418 (neutralized with NaOH). The
names of plasmid constructs are preceded by a lower case
p whereas the vectors derived from them are denoted by a
lower case v.
Sequencing of PBS in proviral DNA
High-molecular weight DNA was isolated from trans-
duced cells by using the Wizard genomic DNA purifica-
tion kit according to the manufacturer’s (Promega)
instructions. The PBS region was amplified by PCR using
Taq polymerase (Invitrogen) and primers PBSFor (5V-
GCTTCTCGCTTCTGTTCGC-3V) and PBSRev (5V-
CCTACCAGAACCACATATCC-3V). These primers were
also used to sequence either the PCR product directly or
clones of the PCR product ligated into the pGEM-T Easy
vector (Promega).
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Transfections are described above and in the figure
legends. Total cellular RNA was collected, blotted, and
probed using the tRNALys,3- and yeast tRNAPhe-specific
oligonucleotides as described before (Kelly et al., 2003).
The oligo used to probe for tRNAPro was 5V-GGGCTC-
GTCCGGGATTTGAACCCGGGACCTCTCG CACCC-
TAAGCGAGAATCATACCCCTAGACCAACGAG-3V. In
vitro transcribed tRNA standards were created using the
T7-MEGAshortscript kit (Ambion, Austin, Tex.). The
template for the transcription of yeast tRNAPhe was
described previously (Kelly et al., 2003). The template
for the transcription of tRNAPro was created by amplifying
pU6Pro via PCR using the two primers 5V-CTGCAGTAA-
TACGACTCACTATAGGCTCGTTGGTCTAGGGGTAT-
3V and 5V-TGGGGGCTCGTCCGGGATTTG-3V. The tem-
plate for the transcription of tRNALys,3 was created by
PCR fill-in using the two overlapping oligos 5V-
TAATACGACTCACTATAGCCCGGATAGCTCAGT
CGGTAGAGCATCAGACTTTTAATC-3 V and 5 V-
TGGCGCCCGAACAGGGACTTGAACCCT GGACCCT-
CAGATTAAAAGTCTGATGCTCTA-3V. Blots were ex-
posed on X-ray film.
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